TOPIC: BIPOLAR DISORDER
IN 2 PAGES EXPLAIN FOR THIS PSYCHOLOGICAL DISORDER ( BIPOLAR DISORDER)
3- differential diagnosis( MENTION 3 ),
4- Disorders Risk,
5- Prognostic Factors.
NO PLAGIO MORE THAN 10 %
DUE DATE APRIL 15, 2023
DSM-5 Criteria for Schizophrenia
Two or more of these symptoms must be present for at
least one month (can be less if being successfully treated)
And at least one symptom must be either (1), (2), or (3)
• (1) Hallucinations
• (2) Delusions (can be either bizarre or nonbizarre)
• (3) Disorganized speech(e.g., frequent derailment or incoherence)
• (4) Grossly disorganized or catatonic behavior
• (5) Negative symptoms (e g., affective flattening, alogia or avolition)
Continuos disturbance for 6 months (attenuated
symptoms, residual symptoms)
Social or occupational dysfunction (or both) for significant
portion of the time
• Notes: Catatonia can
Pharmacological Treatment: Administer ABILIFY 15 mg PO QD: Abilify is a 2nd generation antipsychotic medications. 2nd generation medications are generally preferred because they pose a lower risk of severe side effects than do 1st generation antipsychotics such as fluphenazine, perphenazine, and chlorpromazine (Preda & Shapiro, 2020). The recommended initial and target dose for the medication is 10 or 15 mg QD without regard for meals. The medication has been systematically assessed and shown to be effective in treating symptoms of schizophrenia in a dose range of 10-30 mg/day when administered as the tablet formulation (Preda & Shapiro, 2020). Nonetheless, doses greater than 10 or 15 mg/day were not more effective than 10 or 15 mg/day (Preda & Shapiro, 2020).
Psycho-education: The patient should be educated on a variety of issues that can inhibit or enhance his outcomes. First, he should be educated on the need to follow through with the treatment regimen (Kim et al., 2020). He should also be counselled on the side effects that he may experience due to the use of Abilify. Such include dizziness, drowsiness, vomiting, nausea, fatigue, drooling, weight gain, headache, constipation, lightheadedness, and trouble sleeping (Preda & Shapiro, 2020). He should also be counseled to return to the clinic in case his condition worsens.
Kim, J., Ozzoude, M., Nakajima, S., Shah, P., Caravaggio, F., Iwata, Y., … & Gerretsen, P. (2020). Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology, 168, 107634.
Preda, A., & Shapiro, B. B. (2020). A safety evaluation of aripiprazole in the treatment of SCHIZOPHRENIA. Expert opinion of drug safety, 19(12), 1529-1538.